Obesity Market Outlook: Supply, Pricing, and Next-Generation Assets

The obesity market is experiencing unprecedented growth, driven by semaglutide and tirzepatide. Wegovy and Zepbound have achieved rapid uptake despite reimbursement friction and manufacturing constraints. Cagrisema and retatrutide are positioned to extend efficacy, while maritide's monthly dosing could improve adherence. Oral options from Pfizer, Lilly, and Structure Therapeutics target patients who prefer pills and lower-cost production, though discontinuations like lotiglipron underscore tolerability risks. Cardiovascular risk reduction is becoming a key differentiator following SELECT and pending SURMOUNT-MMOE results.